PACB · Pacific Biosciences Of California, Inc. · Executive Compensation
$2.50
+0.13 (+5.65%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$503.55M
Shares
310.83M
Volume · Oct 1
35.83M
Avg daily vol (3M)
8.02M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Christian O. Henry | President and Chief Executive Officer | $4,309,846 |
| Jim R. Gibson | Chief Financial Officer | $3,493,189 |
| Mark Van Oene | Chief Operating Officer | $2,366,113 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christian O. Henry | President and Chief Executive Officer | $9,181,620 |
| Mark Van Oene | Chief Operating Officer | $4,805,004 |
| Jeff Eidel | Former Chief Commercial Officer | $3,333,167 |
| Susan G. Kim | Former Chief Financial Officer | $2,669,453 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christian O. Henry | President and Chief Executive Officer | $8,046,575 |
| Mark Van Oene | Chief Operating Officer | $4,601,322 |
| Jeff Eidel | Former Chief Commercial Officer | $2,533,727 |
| Susan G. Kim | Former Chief Financial Officer | $2,519,275 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Christian O. Henry | President and Chief Executive Officer | $6,616,251 |
| Mark Van Oene | Chief Operating Officer | $6,563,691 |
| Jeff Eidel | Former Chief Commercial Officer | $5,801,485 |
| Susan G. Kim | Former Chief Financial Officer | $2,618,112 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Van Oene | Chief Operating Officer | $28,299,433 |
| Christian O. Henry | President, Chief Executive Officer | $2,866,931 |
| Susan G. Kim | Chief Financial Officer | $1,279,672 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christian O. Henry | President and Chief Executive Officer | Resigned | 2026-08-05 |
| Mark Van Oene | member of the Board | Appointed | 2026-08-05 |
| Mark Van Oene | President and Chief Executive Officer | Appointed | 2026-08-05 |
| Christopher M. Smith | member of the board of directors | Resigned | 2026-07-09 |
| John F. Milligan, Ph.D. | Class III Director | Appointed | 2026-06-04 |
| Christian O. Henry | Class III Director | Appointed | 2026-06-04 |
| Chris Gibson, Ph.D. | Class III Director | Appointed | 2026-06-04 |
| Christopher M. Smith | Class III Director | Appointed | 2026-06-04 |
| Kathy Ordoñez | Class III Director | Appointed | 2026-06-04 |
| William Ericson | Class III Director | Appointed | 2026-06-04 |
| Michele Farmer | Chief Accounting Officer | Resigned | 2026-03-06 |
| Christopher Gibson, Ph.D. | member of the Company's Science and Technology Committee | Appointed | 2026-03-05 |
| Christopher Gibson, Ph.D. | Class I director | Appointed | 2026-03-05 |
| Christopher M. Smith | Class III Director | Appointed | 2025-06-06 |
| Kathy Ordoñez | Class III Director | Appointed | 2025-06-06 |
| William Ericson | Class III Director | Appointed | 2025-06-06 |
| Jim R. Gibson | Chief Financial Officer | Appointed | 2025-03-27 |
| David Meline | member of the Board | Resigned | 2025-01-30 |
| Christopher M. Smith | Class III director | Appointed | 2025-01-30 |
| Susan G. Kim | Chief Financial Officer and principal financial officer | Resigned | 2024-12-06 |
| Christian Henry | interim Chief Financial Officer | Appointed | 2024-12-06 |
| Jeff Eidel | Chief Commercial Officer | Terminated | 2024-11-12 |
| Susan Kim | Chief Financial Officer | Resigned | 2024-11-07 |
| Hannah A. Valantine, M.D. | Class II Director | Appointed | 2024-06-20 |
| David Meline | Class II Director | Appointed | 2024-06-20 |